Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Keybanc Upgrades GoodRx Holdings to Overweight, Announces $9 Price Target

Author: Benzinga Newsdesk | April 10, 2024 04:40am
Keybanc analyst Scott Schoenhaus upgrades GoodRx Holdings (NASDAQ:GDRX) from Sector Weight to Overweight and announces $9 price target.

Posted In: GDRX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist